| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.2 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.067 | 0.2 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.038 | 0.2 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |